ProQR Therapeutics NV (NASDAQ:PRQR)

6.25
BATS BZX Real-Time Price
As of 3:56pm ET
 -0.12 / -1.88%
Today’s Change
4.05
Today|||52-Week Range
9.46
-21.97%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$480.3M

Company Description

ProQR Therapeutics NV is a biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. Its product pipeline include Sepofarsen, QR-421a, QR-1123, and QR-504a. The company was founded by Daniel de Boer, Gerard Platenburg, Henri Termeer, and Dinko Valerio on February 21, 2012 and is headquartered in Leiden, the Netherlands.

Contact Information

ProQR Therapeutics NV
Zernikedreef 9
Leiden Zuid-holland 2333 CK
P:(188) 166-7000
Investor Relations:

Employees

Shareholders

Other institutional38.29%
Mutual fund holders26.23%
Individual stakeholders--

Top Executives

Daniel Anton de BoerChief Executive Officer
Smital ShahChief Financial & Business Officer
Aniz GirachChief Medical Officer
Jennifer PluimVice President-Medical Affairs
Naveed K. ShamsChief Scientific Officer